Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluating estimated health care resource utilization and costs in patients with myelofibrosis based on transfusion status and anemia severity: A retrospective analysis of the Medicare Fee-For-Service claims data.
Gerds AT, Tkacz J, Moore-Schiltz L, Schinkel J, Phiri K, Liu T, Gorsh B. Gerds AT, et al. Among authors: gorsh b. J Manag Care Spec Pharm. 2024 Dec;30(12):1395-1404. doi: 10.18553/jmcp.2024.24050. Epub 2024 Oct 3. J Manag Care Spec Pharm. 2024. PMID: 39360964 Free PMC article.
Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment.
Thomas C, Ailawadhi S, Popat R, Kleinman D, Ross MM, Gorsh B, Mulnick S, O'Neill A, Paka P, Hanna M, Krucien N, Molinari A, Gelhorn HL, Perera S. Thomas C, et al. Among authors: gorsh b. Front Med (Lausanne). 2023 Nov 23;10:1271657. doi: 10.3389/fmed.2023.1271657. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38076274 Free PMC article.
Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.
Mesa RA, Harrison C, Palmer JM, Gupta V, McLornan DP, McMullin MF, Kiladjian JJ, Foltz L, Platzbecker U, Fox ML, Mead AJ, Ross DM, Oh ST, Perkins AC, Leahy MF, Kawashima J, Ro S, Donahue R, Gorsh B, Deheshi S, Verstovsek S. Mesa RA, et al. Among authors: gorsh b. Hemasphere. 2023 Oct 24;7(11):e966. doi: 10.1097/HS9.0000000000000966. eCollection 2023 Nov. Hemasphere. 2023. PMID: 37901848 Free PMC article.
Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.
Popat R, Lonial S, Voorhees PM, Esposti SD, Gorsh B, Gupta I, Opalinska J, Sapra S, Piontek T, He Z, Kleinman D, Schaumberg D, Regnault A, Meunier J, Eliason L. Popat R, et al. Among authors: gorsh b. J Adv Pract Oncol. 2023 Sep;14(6):503-518. doi: 10.6004/jadpro.2023.14.6.4. Epub 2023 Sep 1. J Adv Pract Oncol. 2023. PMID: 37808071 Free PMC article.
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kortüm KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Gupta I, Opalinska J, Richardson PG, Lonial S. Nooka AK, et al. Among authors: gorsh b. Cancer. 2023 Dec 1;129(23):3746-3760. doi: 10.1002/cncr.34987. Epub 2023 Aug 25. Cancer. 2023. PMID: 37622738 Free PMC article.
27 results